Opioid Alternatives to Codeine

Chemical Classification and Metabolic Pathways

Codeine is a phenanthrene derivative that functions as a prodrug requiring CYP2D6 metabolism to morphine for analgesic effect, according to the American Society of Clinical Oncology 1, 2
Methadone is a synthetic diphenylheptane derivative that acts as a mu-opioid agonist similar to morphine in quality but with completely different chemical structure and metabolism, as stated by the European Society for Medical Oncology 3
Fentanyl is a synthetic phenylpiperidine derivative approximately 50-100 times more potent than morphine, with no structural relationship to codeine, as reported by the European Society for Medical Oncology 3
Hydromorphone is a semi-synthetic opioid with a conversion factor of 4 and has less problematic metabolite accumulation compared to codeine, according to the Centers for Disease Control and Prevention 4, 5

For patients requiring strong opioid therapy, oral morphine remains the guideline-recommended first choice for moderate to severe cancer pain, but methadone, hydromorphone, or fentanyl are appropriate alternatives when codeine-related compounds must be avoided, as recommended by the European Society for Medical Oncology 3, 7
Methadone requires specialist consultation for initiation due to complex pharmacokinetics and risk of drug accumulation, according to the American Society of Clinical Oncology 1, 2
Transdermal fentanyl and buprenorphine patches are best reserved for patients with stable pain already controlled on opioids, as stated by the European Society for Medical Oncology 3
Hydromorphone offers the advantage of smaller volume administration and less metabolite accumulation, according to the Centers for Disease Control and Prevention 5

Approximately 10% of patients are poor CYP2D6 metabolizers, making codeine ineffective in this population, as reported by the Centers for Disease Control and Prevention 5
Codeine requires CYP2D6 for conversion to morphine, according to the American Society of Clinical Oncology 1, 2
Tramadol requires CYP2D6 for conversion to M1 metabolite, as stated by the American Society of Clinical Oncology 1, 6

For moderate pain, consider low-dose strong opioids combined with non-opioid analgesics rather than other "weak" opioids, as recommended by the European Society for Medical Oncology 3, 7
For severe pain requiring parenteral administration, use hydromorphone or fentanyl, according to the Centers for Disease Control and Prevention 5
For patients with renal impairment, prefer fentanyl or methadone over morphine/codeine due to less problematic metabolite accumulation, as stated by the Centers for Disease Control and Prevention 5
For stable chronic pain, consider transdermal fentanyl or buprenorphine patches, as recommended by the European Society for Medical Oncology 3